Seehofer Pledges To Cut German Drug Consumption

18 November 1996

The German Social Democratic Party's social affairs spokesman, Rudolf Dressler, says he fears a drastic increase in the sums which patients insured through the public-sector health funds will have to pay for their drugs and medicines in future, following the government's proposed revised legislation.

From January, each fund premium rise must be matched by higher patient contributions. Mr Dressler says a 1% rise in premiums could mean extra payments by patients rising to as much as 18 Deutschemarks ($10). Increases in premium rates are inevitable, given the high deficits being run by many funds, with some (Mr Dressler cites the Bavarian local health funds) on the verge of bankruptcy.

Indications are that under the draft legislation agreed by the Bonn coalition, a whole range of drugs which are freely available as over-the-counter products in pharmacies and in drugstores will be removed from the health fund sector altogether and no longer reimbursed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight